Study to Assess Food Effect on Sativex Bioavailability

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to assess effect of food on the bioavailability of a single dose of Sativex and to measure its' pharmacokinetics after a single and multiple doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans

NCT01757379

Short Chain Fatty Acids Bioavailability

COMPLETED NA

Assessing the Bioavailability of Leading Phytonutrient Products

NCT05349032

Inflammation

UNKNOWN NA

Bioavailability of N-acylethanolamines: an Ileostomy Study (NAE Study)

NCT05845229

Healthy Nutrition

UNKNOWN NA

Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome

NCT01599169

Efficacy and Tolerance of B-Back® on the Burnout Syndrome

COMPLETED NA

Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women

NCT05025917

Muscle Weakness Osteoporosis, Postmenopausal

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was an open-label, randomised, ascending dose, 2-way crossover food-effect study incorporating a parallel single and multiple dose components in healthy subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 Fasted-Fed

4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.

Followed by 4 sprays daily in fasted state.

Group Type EXPERIMENTAL

Sativex

Intervention Type DRUG

4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Group 1 Fed-Fasted

4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.

Followed by 4 sprays daily in fasted state.

Group Type EXPERIMENTAL

Sativex

Intervention Type DRUG

4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Group 2

2 sprays Sativex daily in fasted state.

Group Type EXPERIMENTAL

Sativex

Intervention Type DRUG

2 sprays Sativex daily in fasted state Days 4-13.

Group 3

8 sprays sativex daily in fasted state.

Group Type EXPERIMENTAL

Sativex

Intervention Type DRUG

8 sprays Sativex daily in fasted state Days 4-13.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sativex

4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Intervention Type DRUG

Sativex

4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Intervention Type DRUG

Sativex

2 sprays Sativex daily in fasted state Days 4-13.

Intervention Type DRUG

Sativex

8 sprays Sativex daily in fasted state Days 4-13.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males between 18 and 45 years of age (inclusive).
* Body mass index to be between 18 to 30 kg/m2 (inclusive) as calculated by weight(Kg)/height(m2).
* Subjects were to have no clinically significant abnormal findings on physical examination, ECG, medical history, or clinical laboratory results during screening.
* Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels.
* Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study).
* Subjects were to have a negative screen for HIV I and II, HBsAg, and antibody to Hepatitis C virus.
* Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine.
* Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug.
* Subjects were able to comply with the protocol and the restrictions and assessments therein.
* Subjects were to give voluntary written informed consent to participate in the trial.

Exclusion Criteria

* Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
* Subjects were not to have any history or presence or family history of schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder.
* Subjects were not to have a postural drop of 20 mmHg or more in systolic blood pressure at screening.
* Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation.
* Subjects were not to have donated plasma within 90 days prior to study initiation.
* Subjects were not to have donated blood within 90 days prior to study initiation.
* Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.
* Subjects were not to have had treatment with any known enzyme-altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.
* Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
* Subjects were not to use any prescription medication within 14 days prior to or during the study.
* Subjects were not to use any over-the-counter medication within 7 days prior to or during the study.
* Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes